Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …

Cutaneous melanoma is one of the highest incident-rate cancers with increasing prevalence
in Western societies. Despite the advent of new approved therapeutics, the 5-year overall …

Purpose: There is a need for sensitive, reproducible biomarkers for patients with stage III
melanoma to guide clinical decision making. Circulating tumor cells (CTCs) can be detected …

Liquid biopsy refers to the molecular analysis in biological fluids of nucleic acids, subcellular
structures, especially exosomes, and, in the context of cancer, circulating tumor cells. In the …

Despite continuous improvements in cancer management, locoregional recurrence or
metastatic spread still occurs in a high proportion of patients after radiotherapy or combined …

Circulating tumour cells (CTCs) are cells of solid tumour origin detectable in the peripheral
blood. Their occurrence is considered a prerequisite step for establishing distant …

Melanoma and Merkel cell carcinoma are two aggressive skin malignancies with high
disease-related mortality and increasing incidence rates. Currently, invasive tumor tissue …

Different molecular markers have been identified for melanoma-initiating cells including
CD133 and nestin. Assuming that metastasis requires a dissemination of tumor-initiating …

Melanoma is an aggressive tumor with increasing incidence worldwide. Biomarkers are
valuable tools to minimize the cost and improve efficacy of treatment of this deadly disease …

During the last six years, several innovative, systemic therapies for the treatment of
metastatic malignant melanoma (MM) have emerged. Conventional chemotherapy has been …